Core Viewpoint - A class action lawsuit has been filed against aTyr Pharma, Inc. for alleged violations of federal securities laws during the specified class period [1][2][3]. Group 1: Lawsuit Details - The lawsuit seeks to recover damages for investors who purchased aTyr securities between January 16, 2025, and September 12, 2025 [2]. - The Complaint alleges that aTyr's executives made materially false and misleading statements regarding the drug Efzofitimod, particularly about its efficacy and the ability for patients to taper steroid usage [3]. Group 2: Next Steps for Investors - Investors who suffered losses in aTyr have until December 8, 2025, to request to be appointed as lead plaintiff in the case [4]. - A copy of the Complaint can be reviewed on the law firm's website [4]. Group 3: Legal Representation - The law firm operates on a contingency fee basis, meaning they will only seek reimbursement for expenses and fees if successful in the lawsuit [5]. - Bronstein, Gewirtz & Grossman, LLC is recognized for representing investors in securities fraud class actions and has recovered hundreds of millions for investors [6].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against aTyr Pharma, Inc. due to allegations of securities law violations related to misleading statements about the efficacy of its drug, efzofitimod, which led to significant financial losses for investors [2][4]. Group 1: Legal Investigation and Class Action - The firm is encouraging investors who suffered losses in aTyr between January 16, 2025, and September 12, 2025, to discuss their legal options [1]. - There is a deadline of December 9, 2025, for investors to seek the role of lead plaintiff in a federal securities class action against aTyr [2]. - The lead plaintiff is defined as the investor with the largest financial interest who directs the litigation on behalf of the class [6]. Group 2: Allegations Against aTyr Pharma - The complaint alleges that aTyr and its executives made false and misleading statements regarding the drug efzofitimod, particularly about its ability to allow patients to taper off steroids completely [4]. - The EFZO-FIT study results indicated that efzofitimod did not show a significant change in mean daily oral corticosteroid dose at week 48, with a reduction of only 2.79 mg for the drug compared to 3.52 mg for placebo [5]. - Following the release of these results, aTyr's stock plummeted by 83.25%, dropping from $6.03 to $1.01 [5]. Group 3: Call for Information - Faruqi & Faruqi is also seeking information from whistleblowers, former employees, and shareholders regarding aTyr's conduct [7].

NEW YORK, Oct. 12, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of common stock of aTyr Pharma, Inc. (NASDAQ: ATYR) between January 16, 2025 and September 12, 2025, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 8, 2025. SO WHAT: If you purchased aTyr Pharma common stock du ...

Core Points - A class action has been filed on behalf of investors who purchased aTyr Pharma, Inc. common stock between January 16, 2025, and September 12, 2025 [1] - The allegations involve misleading statements regarding the efficacy of aTyr's drug candidate, Efzofitimod, during a Phase 3 clinical trial for pulmonary sarcoidosis [2] - Following the announcement that the EFZO-FIT study did not meet its primary endpoint, aTyr's stock price plummeted by 83.2%, from $6.03 to $1.02 per share in one day [3] Company Overview - aTyr Pharma, Inc. is a clinical stage biotechnology company focused on developing therapies for fibrosis and inflammation through evolutionary intelligence [1] Legal Proceedings - Shareholders wishing to serve as lead plaintiffs in the class action must submit their papers by December 8, 2025 [4] - The representation in the class action is on a contingency fee basis, meaning shareholders incur no fees or expenses [5]

LOS ANGELES--(BUSINESS WIRE)--aTyr Pharma, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – ATYR. ...

Core Viewpoint - ATYR Investors are presented with an opportunity to lead a securities fraud lawsuit against aTyr Pharma, Inc. in collaboration with the Schall Law Firm [1] Group 1 - The lawsuit is focused on allegations of securities fraud involving aTyr Pharma, Inc. [1] - The Schall Law Firm is actively seeking investors who wish to participate in the lawsuit [1] - This legal action may provide a platform for investors to address grievances related to the company's practices [1]

Core Viewpoint - Rosen Law Firm has announced the filing of a class action lawsuit on behalf of purchasers of aTyr Pharma, Inc. common stock during the specified Class Period, highlighting potential investor compensation opportunities [1][2]. Group 1: Class Action Details - The class action lawsuit pertains to aTyr Pharma, Inc. common stock purchases made between January 16, 2025, and September 12, 2025 [1]. - Investors who purchased shares during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A lead plaintiff must move the Court by December 8, 2025, to represent other class members in the litigation [1][3]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as the Rosen Law Firm has significant experience and success in this area [4]. - The firm has achieved notable settlements, including the largest securities class action settlement against a Chinese company at the time, and has recovered hundreds of millions for investors [4]. Group 3: Case Allegations - The complaint alleges that defendants made misleading statements regarding the efficacy of Efzofitimod, particularly concerning its ability to allow patients to taper steroid usage completely [5]. - The lawsuit claims that when the true details were revealed, investors suffered damages due to the misleading information [5].

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action lawsuit on behalf of purchasers and acquirers of aTyr Pharma, Inc. (NASDAQ: ATYR) common stock between January 16, 2025 and September 12, 2025, both dates inclusive (the "Class Period†). aTyr is a clinical stage biotechnology company. For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen Law Firm is I. ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against aTyr Pharma, Inc. due to allegations of misleading statements regarding the efficacy of its drug efzofitimod, which led to significant financial losses for investors [4][6]. Group 1: Legal Investigation - The firm is encouraging investors who suffered losses in aTyr between January 16, 2025, and September 12, 2025, to discuss their legal rights [1][4]. - A federal securities class action has been filed against aTyr, with a deadline of December 9, 2025, for investors to seek the role of lead plaintiff [4][8]. Group 2: Allegations Against aTyr - The complaint alleges that aTyr and its executives violated federal securities laws by making false and misleading statements about efzofitimod, particularly regarding its ability to allow patients to taper off steroid usage [6]. - The EFZO-FIT study results indicated that efzofitimod did not show a significant reduction in mean daily oral corticosteroid (OCS) dose compared to placebo, with only 52.6% of patients achieving complete steroid withdrawal [7]. Group 3: Stock Performance Impact - Following the release of the study results, aTyr's stock plummeted by 83.25%, dropping from a market close of $6.03 on September 12 to $1.01 on September 15 [7].

Core Viewpoint - A securities class action lawsuit has been filed against aTyr Pharma, Inc. for allegedly disseminating false and misleading statements regarding the efficacy of its drug Efzofitimod during a clinical trial [1][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who purchased aTyr Pharma common stock between January 16, 2025, and September 12, 2025, with a lead plaintiff deadline set for December 8, 2025 [1][6]. - The complaint claims that aTyr Pharma concealed material adverse facts about Efzofitimod's ability to allow patients to taper steroid usage [3]. Group 2: Clinical Trial Results - aTyr Pharma conducted a Phase 3 study (EFZO-FIT) to evaluate Efzofitimod's safety and efficacy in patients with pulmonary sarcoidosis [3]. - On September 15, 2025, aTyr Pharma announced that the EFZO-FIT study failed to meet its primary endpoint regarding the reduction of mean daily oral corticosteroid dose at week 48 [4]. Group 3: Stock Price Impact - Following the announcement of the disappointing trial results, aTyr Pharma's stock price plummeted by 83.2%, dropping from $6.03 per share on September 12, 2025, to $1.02 per share on September 15, 2025 [5]. Group 4: Legal Representation - Investors affected by the stock price decline are encouraged to contact Shamis & Gentile, P.A. for information on seeking recovery claims [2][6].